212 related articles for article (PubMed ID: 36768931)
21. Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection.
Cham LB; Torrez Dulgeroff LB; Tal MC; Adomati T; Li F; Bhat H; Huang A; Lang PA; Moreno ME; Rivera JM; Galkina SA; Kosikova G; Stoddart CA; McCune JM; Myers LM; Weissman IL; Lang KS; Hasenkrug KJ
Cell Rep; 2020 Apr; 31(2):107494. PubMed ID: 32294445
[TBL] [Abstract][Full Text] [Related]
22. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
23. Thrombospondin-1, CD47, and SIRPα display cell-specific molecular signatures in human islets and pancreata.
Erdem N; Chen KT; Qi M; Zhao Y; Wu X; Garcia I; Ku HT; Montero E; Al-Abdullah IH; Kandeel F; Roep BO; Isenberg JS
Am J Physiol Endocrinol Metab; 2023 Apr; 324(4):E347-E357. PubMed ID: 36791324
[TBL] [Abstract][Full Text] [Related]
24. Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion.
Barazi HO; Li Z; Cashel JA; Krutzsch HC; Annis DS; Mosher DF; Roberts DD
J Biol Chem; 2002 Nov; 277(45):42859-66. PubMed ID: 12218055
[TBL] [Abstract][Full Text] [Related]
25. Impaired Antitumor Immune Response in
Kacher J; Manches O; Aspord C; Sartelet H; Chaperot L
Cancer Res Commun; 2022 Jul; 2(7):577-589. PubMed ID: 36923280
[TBL] [Abstract][Full Text] [Related]
26. Regulation of MYCN expression in human neuroblastoma cells.
Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
[TBL] [Abstract][Full Text] [Related]
27. Cordycepin enhances anti-tumor immunity in colon cancer by inhibiting phagocytosis immune checkpoint CD47 expression.
Deng Q; Li X; Fang C; Li X; Zhang J; Xi Q; Li Y; Zhang R
Int Immunopharmacol; 2022 Jun; 107():108695. PubMed ID: 35305385
[TBL] [Abstract][Full Text] [Related]
28. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
29. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
30. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
Kamijo H; Miyagaki T; Takahashi-Shishido N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Leukemia; 2020 Mar; 34(3):845-856. PubMed ID: 31712778
[TBL] [Abstract][Full Text] [Related]
31. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
32. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.
Salib A; Jayatilleke N; Seneviratne JA; Mayoh C; De Preter K; Speleman F; Cheung BB; Carter DR; Marshall GM
Oncogene; 2024 Jan; 43(5):363-377. PubMed ID: 38049564
[TBL] [Abstract][Full Text] [Related]
33. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
34. TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction.
Rogers NM; Sharifi-Sanjani M; Yao M; Ghimire K; Bienes-Martinez R; Mutchler SM; Knupp HE; Baust J; Novelli EM; Ross M; St Croix C; Kutten JC; Czajka CA; Sembrat JC; Rojas M; Labrousse-Arias D; Bachman TN; Vanderpool RR; Zuckerbraun BS; Champion HC; Mora AL; Straub AC; Bilonick RA; Calzada MJ; Isenberg JS
Cardiovasc Res; 2017 Jan; 113(1):15-29. PubMed ID: 27742621
[TBL] [Abstract][Full Text] [Related]
35. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
36. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
37. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
38. CD47 promotes peripheral T cell survival by preventing dendritic cell-mediated T cell necroptosis.
Komori S; Saito Y; Nishimura T; Respatika D; Endoh H; Yoshida H; Sugihara R; Iida-Norita R; Afroj T; Takai T; Oduori OS; Nitta E; Kotani T; Murata Y; Kaneko Y; Nitta R; Ohnishi H; Matozaki T
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2304943120. PubMed ID: 37549290
[TBL] [Abstract][Full Text] [Related]
39. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.
Kaur S; Kuznetsova SA; Pendrak ML; Sipes JM; Romeo MJ; Li Z; Zhang L; Roberts DD
J Biol Chem; 2011 Apr; 286(17):14991-5002. PubMed ID: 21343308
[TBL] [Abstract][Full Text] [Related]
40. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
